BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
126 results:

  • 1.
    Vaddi PK; Osborne DG; Nicklawsky A; Williams NK; Menon DR; Smith D; Mayer J; Reid A; Domenico J; Nguyen GH; Robinson WA; Ziman M; Gao D; Zhai Z; Fujita M
    Front Immunol; 2023; 14():1173035. PubMed ID: 37197667
    [TBL] [Abstract] [Full Text] [Related]  

  • 2.
    Suzuki T; Takei J; Fukasawa N; Suzuki K; Ogawa D; Yamamoto Y; Akasaki Y; Murayama Y; Shimoda M; Miyake K; Tanaka T
    World Neurosurg; 2023 Jul; 175():e1364-e1374. PubMed ID: 37187346
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
    Liao P; Jiang M; Islam MS; Wang Y; Chen X
    Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Upregulated Immunogenic cell-Death-Associated Gene Signature Predicts Reduced Responsiveness to Immune-Checkpoint-Blockade Therapy and Poor Prognosis in High-Grade Gliomas.
    Tang X; Guo D; Yang X; Chen R; Jiang Q; Zeng Z; Li Y; Li Z
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429083
    [No Abstract]    [Full Text] [Related]  

  • 5. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
    Shui IM; Liu XQ; Zhao Q; Kim ST; Sun Y; Yearley JH; Choudhury T; Webber AL; Krepler C; Cristescu R; Lee J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793874
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.
    Hosseinalizadeh H; Mahmoodpour M; Samadani AA; Roudkenar MH
    Med Oncol; 2022 Jun; 39(9):130. PubMed ID: 35716323
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
    Gartrell RD; Enzler T; Kim PS; Fullerton BT; Fazlollahi L; Chen AX; Minns HE; Perni S; Weisberg SP; Rizk EM; Wang S; Oh EJ; Guo XV; Chiuzan C; Manji GA; Bates SE; Chabot J; Schrope B; Kluger M; Emond J; Rabadán R; Farber D; Remotti HE; Horowitz DP; Saenger YM
    Oncoimmunology; 2022; 11(1):2066767. PubMed ID: 35558160
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment.
    Star P; Jackett LA; Cheung K; Wilmott JS; Ho G; Smith A; Long GV; Scolyer RA; Martin LK
    Dermatol Ther; 2022 Jun; 35(6):e15472. PubMed ID: 35347815
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
    Bozhanova G; Hassan J; Appleton L; Jennings V; Foo S; McLaughlin M; Chan Wah Hak CM; Patin EC; Crespo-Rodriguez E; Baker G; Armstrong E; Chiu M; Pandha H; Samson A; Roulstone V; Kyula J; Vile R; Errington-Mais F; Pedersen M; Harrington K; Ono M; Melcher A
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338089
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients.
    Cuadrado-Vilanova M; Liu J; Paco S; Aschero R; Burgueño V; Sirab N; Pascual-Pasto G; Correa G; Balaguer-Lluna L; Castillo-Ecija H; Perez-Jaume S; Muñoz-Aznar O; Roldan M; Suñol M; Schaiquevich P; Aerts I; Doz F; Cassoux N; Lubieniecki F; Benitez-Ribas D; Lavarino C; Mora J; Chantada GL; Catala-Mora J; Radvanyi F; Carcaboso AM
    J Pathol; 2022 Jul; 257(3):327-339. PubMed ID: 35254670
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
    Choi J; Medikonda R; Saleh L; Kim T; Pant A; Srivastava S; Kim YH; Jackson C; Tong L; Routkevitch D; Jackson C; Mathios D; Zhao T; Cho H; Brem H; Lim M
    Oncoimmunology; 2021; 10(1):1956142. PubMed ID: 34484870
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Retargeting IL-2 Signaling to NKG2D-Expressing tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy.
    Banerjee A; Li D; Guo Y; Mahgoub B; Paragas L; Slobin J; Mei Z; Manafi A; Hata A; Li K; Shi L; Westwick J; Slingluff C; Lazear E; Krupnick AS
    J Immunol; 2021 Jul; 207(1):333-343. PubMed ID: 34155069
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
    Crotty EE; Smith SMC; Brasel K; Pakiam F; Girard EJ; Connor YD; Zindy F; Mhyre AJ; Roussel MF; Olson JM
    J Neurooncol; 2021 Jun; 153(2):225-237. PubMed ID: 33963961
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
    Tosi A; Cappellesso R; Dei Tos AP; Rossi V; Aliberti C; Pigozzo J; Fabozzi A; Sbaraglia M; Blandamura S; Del Bianco P; Chiarion-Sileni V; Rosato A
    J Exp Clin Cancer Res; 2021 May; 40(1):154. PubMed ID: 33947438
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
    Somasundaram R; Connelly T; Choi R; Choi H; Samarkina A; Li L; Gregorio E; Chen Y; Thakur R; Abdel-Mohsen M; Beqiri M; Kiernan M; Perego M; Wang F; Xiao M; Brafford P; Yang X; Xu X; Secreto A; Danet-Desnoyers G; Traum D; Kaestner KH; Huang AC; Hristova D; Wang J; Fukunaga-Kalabis M; Krepler C; Ping-Chen F; Zhou X; Gutierrez A; Rebecca VW; Vonteddu P; Dotiwala F; Bala S; Majumdar S; Dweep H; Wickramasinghe J; Kossenkov AV; Reyes-Arbujas J; Santiago K; Nguyen T; Griss J; Keeney F; Hayden J; Gavin BJ; Weiner D; Montaner LJ; Liu Q; Peiffer L; Becker J; Burton EM; Davies MA; Tetzlaff MT; Muthumani K; Wargo JA; Gabrilovich D; Herlyn M
    Nat Commun; 2021 Jan; 12(1):346. PubMed ID: 33436641
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A novel foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
    Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
    Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. C6 cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.
    Singh D; Dromel PC; Perepelkina T; Baranov P; Young M
    Cell Transplant; 2020; 29():963689720964383. PubMed ID: 33356508
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Presence of tumor-infiltrating CD8
    Johansson J; Siarov J; Kiffin R; Mölne J; Mattsson J; Naredi P; Olofsson Bagge R; Martner A; Lindnér P
    Oncoimmunology; 2020 Dec; 9(1):1854519. PubMed ID: 33344043
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.